{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-031374","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2025-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.890130+00:00","generated_at":"2026-05-17T12:22:10.906287+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aquestive prices $85M common stock offering of 21.25M shares at $4.00/share","bullets":["Offers 21.25M shares at $4.00/share; expected gross proceeds $85M, closing Aug 15, 2025.","Proceeds to primarily fund launch/commercialization of Anaphylm (epinephrine sublingual film) pending FDA approval.","Offering led by RTW Investments; includes Samsara BioCapital, EcoR1 Capital, Perceptive Advisors, others.","Joint bookrunning managers: Leerink Partners, Cantor, Oppenheimer; H.C. Wainwright lead manager."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-031374","json":"https://secwatch.observer/filing/0001140361-25-031374.json","markdown":"https://secwatch.observer/filing/0001140361-25-031374.md","text":"https://secwatch.observer/filing/0001140361-25-031374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/0001140361-25-031374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/ef20053945_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:22:10.906287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}